Restrictions to be put on two medicines are being urged by the European Medicines Agency (EMA), which concerns the drugs can cause more harms than the benefits these provide, as per a report uncovered recently.

It has been found that the medications containing tolperisone and trimetazidine are being asked to be replaced or simply removed.

European drugs regulators say that tolperisone, a generic muscle relaxant medicine, used to treat muscle spasms and spasticity can many a times lead to hypersensitivity reactions. They claim that while its risks always overshadow its benefits, the same only works the other way round in case of adults having post-stroke spasticity.

Also, it ensures benefits when is used as an oral formulation, they added. Further, they criticize trimetazidine too, saying it should be confined only to an add-on or a second-line therapy. The generic drug is largely prescribed for tinnitus or vertigo patients, or it is given to those with angina pectoris or sufferers of disturbances in vision.

The report finds that the EMA is currently involved in carrying out a strict investigation into the flaws made by drugmakers in reporting medicine-safety.

Roche is being asked to revise its practices covering drug safety reporting as many lives are being put at risk.